Category: Parkinson’s Disease: Clinical Trials
Objective: Evaluate the impact of IPX203 on the duration of “Good On” intervals and daily motor fluctuations in patients with PD after switching from other levodopa-based therapies.
Background: IPX203 is a novel extended-release carbidopa-levodopa formulation containing a mucoadhesive polymer, designed to improve levodopa delivery and absorption.
Method: ELEVATE-PD is an ongoing real-world, open-label phase 4 study where PD patients are converted from prior levodopa-based therapies (IR CD/LD, IR + COMT inhibitors, IPX066) to IPX203. Following a 5-week dose-optimization period and a 1-week stable dosing, patients are followed for 12 months. The average duration of continuous “Good On” intervals and daily number of motor fluctuations were assessed using data from patient PD diaries. This interim analysis includes 111 patients who completed Day 42/Visit 4.
Results: At baseline, mean duration of continuous “Good On” intervals across all treatment groups was 2.92 ± 1.38 hrs and average number of daily motor fluctuations was 5.86 ± 1.99 hrs. IPX203 treatment increased mean duration of continuous “Good On” intervals to 6.65 hrs (+3.94 hrs increase) for patients switching from IR CD/LD (n=74), to 3.46 hrs (+0.99 hrs increase) from IR + COMT inhibitor (n=9), to 6.58 hrs (+3.09 hrs increase) from IPX066 (n=22). Moreover, switching to IPX203 resulted in a reduction in the average number of daily motor fluctuations; it decreased to 2.96 (-3.25 [52.85%] reduction) in subjects converting from IR CD/LD, 5.15 (-1.11 [17.73%] reduction) from IR + COMT inhibitor and 2.79 (-1.92 [40.42%] reduction) from IPX066.
Conclusion: The longer duration of continuous “Good On” intervals and reduction of motor fluctuations after switching to IPX203 provide greater time and predictability for patients with PD “Off” fluctuations to perform their daily activities.
To cite this abstract in AMA style:
S. Isaacson, L. Cloud, D. Kreitzman, S. Brillman, G. Banisadr, S. Fisher, R. Hauser. Switching to IPX203 Significantly Increases the Duration of “Good On” Intervals: Interim Real-World Results from the First 111 Patients in ELEVATE-PD [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/switching-to-ipx203-significantly-increases-the-duration-of-good-on-intervals-interim-real-world-results-from-the-first-111-patients-in-elevate-pd/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/switching-to-ipx203-significantly-increases-the-duration-of-good-on-intervals-interim-real-world-results-from-the-first-111-patients-in-elevate-pd/